FIGURE 2.

Absolute change from baseline in a) forced expiratory volume in 1 s (FEV₁) percentage predicted, b) sweat chloride concentration, c) Cystic Fibrosis Questionnaire-Revised (CFQ-R) respiratory domain score and d) body mass index (BMI) in participants with F508del–minimal function genotypes by study visit, each based on a mixed-effects model for repeated measures. Data presented are least squares means, with I-bars indicating standard error of the mean. White shading corresponds to the parent study (Study 445-102) and grey shading corresponds to the extension study. CFQ-R respiratory domain scores (c) are normalised to a 100-point range, with higher scores indicating higher patient-reported quality of life with regard to respiratory symptoms. The minimal clinically important difference for CFQ-R respiratory domain score is 4 points. ELX/TEZ/IVA: elexacaftor/tezacaftor/ivacaftor.